These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27206913)

  • 41. From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI.
    Tenekecioglu E; Bourantas C; Abdelghani M; Zeng Y; Silva RC; Tateishi H; Sotomi Y; Onuma Y; Yılmaz M; Serruys PW
    Expert Rev Med Devices; 2016; 13(3):271-86. PubMed ID: 26782080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical outcomes following bifurcation double-stenting with bioresorbable scaffolds.
    Tanaka A; Latib A; Kawamoto H; Jabbour RJ; Mangieri A; Pagnesi M; Montalto C; Regazzoli D; Ancona M; Chieffo A; Carlino M; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):854-862. PubMed ID: 27184769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Expansion in calcific lesions and overall clinical outcomes following bioresorbable scaffold implantation optimized with intravascular ultrasound.
    Kawamoto H; Ruparelia N; Latib A; Miyazaki T; Sato K; Tanaka A; Naganuma T; Sticchi A; Chieffo A; Carlino M; Montorfano M; Colombo A
    Catheter Cardiovasc Interv; 2017 Apr; 89(5):789-797. PubMed ID: 27545845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Bioresorbable scaffolds: zebras are not striped horses.
    Tarantini G; Cardaioli F
    Catheter Cardiovasc Interv; 2022 Mar; 99(4):1084-1085. PubMed ID: 35441824
    [No Abstract]   [Full Text] [Related]  

  • 45. Bioresorbable vascular scaffold in patients with complex coronary artery disease.
    Tamburino CI; Capranzano P; Longo G; Immè S; Tamburino G; Scalia M; Condorelli A; Francaviglia B; LA Manna A; Sgroi C; Grasso C; DI Salvo ME; Capodanno D; Tamburino C
    Minerva Cardioangiol; 2016 Aug; 64(4):481-6. PubMed ID: 27128353
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.
    Kitabata H; Waksman R; Warnack B
    Cardiovasc Revasc Med; 2014 Mar; 15(2):109-16. PubMed ID: 24684760
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biodegradable-Polymer Biolimus-Eluting Stents versus Durable-Polymer Everolimus-Eluting Stents at One-Year Follow-Up: A Registry-Based Cohort Study.
    Parsa E; Saroukhani S; Majlessi F; Poorhosseini H; Lofti-Tokaldany M; Jalali A; Salarifar M; Nematipour E; Alidoosti M; Aghajani H; Amirzadegan A; Kassaian SE
    Tex Heart Inst J; 2016 Apr; 43(2):126-30. PubMed ID: 27127426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioresorbable scaffolds for the treatment of coronary artery disease: current status and future perspective.
    Kraak RP; Grundeken MJ; Koch KT; de Winter RJ; Wykrzykowska JJ
    Expert Rev Med Devices; 2014 Sep; 11(5):467-80. PubMed ID: 25087771
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Feasibility and efficacy of bioresorbable vascular scaffolds use for the treatment of in-stent restenosis and a bifurcation lesion in a heavily calcified diffusely diseased vessel.
    Naganuma T; Costopoulos C; Latib A; Sato K; Miyazaki T; Colombo A
    JACC Cardiovasc Interv; 2014 May; 7(5):e45-6. PubMed ID: 24746654
    [No Abstract]   [Full Text] [Related]  

  • 50. [Research Progress of Bioresorbable Scaffold].
    Liu Q; Cui S; Zhao Q; Chen M; Zheng B; Huo Y
    Zhongguo Yi Liao Qi Xie Za Zhi; 2017 Sep; 41(5):357-361. PubMed ID: 29862725
    [TBL] [Abstract][Full Text] [Related]  

  • 51. First US experience following FDA approval of the ABBOTT vascular bioresorbable vascular scaffold for the treatment of coronary artery disease.
    Rizik DG; Shah MG; Burke RF
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):899-901. PubMed ID: 27545489
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A longer look at trial evidence of bioresorbable vascular scaffolds.
    Brugaletta S; Sabate M
    Heart; 2017 Jul; 103(14):1061-1062. PubMed ID: 28232379
    [No Abstract]   [Full Text] [Related]  

  • 53. In-scaffold restenosis in a previous left main bifurcation lesion treated with bioresorbable scaffold v-stenting.
    Miyazaki T; Panoulas VF; Sato K; Kawamoto H; Naganuma T; Latib A; Colombo A
    JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):e7-e10. PubMed ID: 25499306
    [No Abstract]   [Full Text] [Related]  

  • 54. Current and future perspectives on drug-eluting bioresorbable coronary scaffolds.
    Ielasi A; Tespili M
    Future Cardiol; 2014 May; 10(3):409-20. PubMed ID: 24976477
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 56. "Full bioresorbable jacket": Alternative to very long segment metallic stenting in a young patient with diffuse coronary artery disease.
    Robaei D; Carlyle A; Jepson N
    Int J Cardiol; 2016 Nov; 223():361-363. PubMed ID: 27543710
    [No Abstract]   [Full Text] [Related]  

  • 57. Preliminary Report of Clinical Outcomes After Single Crossover Bioresorbable Scaffold Implantation Without Routine Side Branch Strut Dilation.
    Tanaka A; Jabbour RJ; Kawamoto H; Mangieri A; Pagnesi M; Montalto C; Chieffo A; Carlino M; Montorfano M; Latib A; Colombo A
    Catheter Cardiovasc Interv; 2016 Nov; 88(6):865-870. PubMed ID: 27219102
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bioresorbable Scaffolds Versus Metallic Drug-Eluting Stents: Are We Getting Any Closer to a Paradigm Shift?
    Windecker S; Koskinas KC; Siontis GCM
    J Am Coll Cardiol; 2015 Dec; 66(21):2310-2314. PubMed ID: 26471804
    [No Abstract]   [Full Text] [Related]  

  • 59. Mid- to long-term outcome of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Data of the BVS registry Göttingen predominantly from ACS patients.
    Hellenkamp K; Becker A; Gabriel YD; Hasenfuß G; Hünlich M; Jacobshagen C; Schillinger W; Schroeter MR
    Int J Cardiol; 2017 May; 234():58-63. PubMed ID: 28258843
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Case illustration of the difference between bench test and in-vivo scaffold fracture thresholds.
    Tanaka A; Jabbour RJ; Latib A; Colombo A
    Int J Cardiol; 2016 Dec; 225():20-22. PubMed ID: 27697666
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.